Physician profile
Stanley Hatcher
NPI 1801344064
$4,190.22
in general payments reported to CMS, 2019-2025
21 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $321 · 2023: $1,399 · 2024: $1,402 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,869.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,160.16 | 2022-2025 | Wavewriter Alpha Prime 16, Spectra Wavewriter |
| Abbott Laboratories | $777.87 | 2023-2025 | Proclaim, Eterna |
| Medtronic, INC. | $529.21 | 2023-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $356.05 | 2022-2025 | Relistor |
| Abbvie INC. | $333.41 | 2022-2025 | |
| Spr Therapeutics, INC | $155.60 | 2025 | Sprint Pns System |
| Mml US, INC. | $149.84 | 2023 | Reactiv8 |
| Bioventus LLC | $137.78 | 2023-2024 | Durolane, Durolane |
| Biohaven Pharmaceutical Holding Company LTD. | $112.34 | 2022 | |
| Relievant Medsystems, INC. | $107.36 | 2022-2023 | Intracept |
| Tersera Therapeutics LLC | $89.34 | 2022-2025 | Prialt |
| Vertex Pharmaceuticals Incorporated | $81.78 | 2024-2025 | |
| Stryker Corporation | $35.64 | 2025 | Optablate |
| Avanos Medical | $33.87 | 2023 | Coolief* Cooled Radiofrequency |
| Spinal Simplicity, LLC | $22.71 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $21.66 | 2023 | Lyvispah |
| Collegium Pharmaceutical, INC. | $20.89 | 2023 | Xtampza |
| Kyowa Kirin, INC. | $18.52 | 2024 | Crysvita |
| Hikma Pharmaceuticals USA | $16.90 | 2022 | |
| Pfizer INC. | $16.22 | 2023 | |
| Grt US Holding, INC. | $13.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Hatcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.